Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo

International Journal of Pediatric Obesity

Volumn 6, Issue 2, 2011, Pages 95-101

  Chanoine, Jean Pierre ^a,c   Richard, Matthew ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Spurwink   (United States)

^c BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Adolescent; anti obesity agents; orlistat; randomized controlled trial; secondary analysis

Indexed keywords

TETRAHYDROLIPSTATIN;

ADOLESCENCE; ADOLESCENT; ARTICLE; BODY MASS; CALORIC RESTRICTION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBESITY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCHOOL CHILD; SECONDARY ANALYSIS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION;

ADOLESCENT; ANTI-OBESITY AGENTS; BODY MASS INDEX; FEMALE; HUMANS; LACTONES; MALE; OBESITY; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 79957468976     PISSN: 17477166     EISSN: 17477174     Source Type: Journal    
DOI: 10.3109/17477166.2010.519387     Document Type: Article

References (31)

1. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61. (Pubitemid 38196725)
2. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42. (Pubitemid 29058112)
3. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo- controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-72. (Pubitemid 28327800)
4. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873-83. (Pubitemid 41029141)
5. Viner RM, Hsia Y, Neubert A, et al. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population- based study. Br J Clin Pharmacol. 2009;68:844-51.
6. Rissanen A, Lean M, Rossner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidencebased assessment of prescribing guidelines. Int J Obes Relat Metab Disord. 2003;27:103-9. (Pubitemid 36152787)
7. Berkey CS, Colditz GA. Adiposity in adolescents: change in actual BMI works better than change in BMI z score for longitudinal studies. Ann Epidemiol. 2007;17:44-50. (Pubitemid 44920373)
8. Cole TJ, Faith MS, Pietrobelli A, et al. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr. 2005;59: 419-25. (Pubitemid 40403297)
9. European Medicines Agency. Xenical: Summary of product characteristics. www.ema.europa.eu/humandocs/PDFs/EPAR/Xenical/H-154-PI-en.pdf (Accessed on May 26, 2010)
10. Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev. 2004;5 Suppl 1:4-104. (Pubitemid 38967209)
11. Whitlock EP, Williams SB, Gold R, et al. Screening and interventions for childhood overweight: a summary of evidence for the US Preventive Services Task Force. Pediatrics. 2005;116:e125-44. (Pubitemid 44017471)
12. Czernichow S, Lee CM, Barzi F, et al. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev. 2010;11:150-8.
13. Viner RM, Hsia Y, Tomsic T, et al. Efficacy and safety of antiobesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev. 2010;11:593-602.
14. Reinehr T, Temmesfeld M, Kersting M, et al. Four-year follow- up of children and adolescents participating in an obesity intervention program. Int J Obes (Lond). 2007;31: 1074-7. (Pubitemid 46987777)
15. Astrup A, Rossner S. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes Rev. 2000;1:17-9.
16. Stotland SC, Larocque M. Early treatment response as a predictor of ongoing weight loss in obesity treatment. Br J Health Psychol. 2005;10 (Pt 4):601-14. (Pubitemid 41564487)
17. Rogovik A, Chanoine JP, Goldman R. Pharmacotherapy and weight loss supplements for treatment of pediatric obesity. Pediatr Drugs. 2010;70:335-46.
18. Lau DC, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007;176:S1-13.
19. Sellers EAC. Pharmacotherapy and bariatric surgery for the treatment of obesity in children and adolescents. CMAJ. 2007;176(8):S89-91.
20. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699-708. (Pubitemid 41601074)
21. Demarchi B, Vos R, Deprez P, et al. Infl uence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal. Aliment Pharmacol Ther. 2004;19:1261-8. (Pubitemid 38859502)
22. Svendsen M, Helgeland M, Tonstad S. The long-term infl uence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. J Hum Nutr Diet. 2009;22:55-63.
23. Svendsen M, Rissanen A, Richelsen B, et al. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring). 2008;16: 327-33. (Pubitemid 351271912)
24. Franson K, Rossner S. Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor. J Intern Med. 2000;247(5):607-14. (Pubitemid 30318065)
25. Damci T, Yalin S, Balci H, et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care. 2004;27:1077-80. (Pubitemid 38579769)
26. Sari R, Balci MK, Coban E, et al. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord. 2004;28:1059-63. (Pubitemid 38998713)
27. Erondu N, Addy C, Lu K, et al. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring). 2007;15:2027-42. (Pubitemid 47402235)
28. Sari R, Balci MK, Cakir M, et al. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004;30:159-67. (Pubitemid 39243118)
29. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother. 2004;58: 582-7. (Pubitemid 40260381)
30. Heal DJ, Aspley S, Prow MR, et al. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfl uramine. Int J Obes Relat Metab Disord. 1998;22 Suppl 1:S18-28;discussion: S29. (Pubitemid 128705406)
31. Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta. 1988;962:308-16.